Home › Non-Small Cell Lung Cancer › Pennsylvania › York
Non-Small Cell Lung Cancer clinical trials in York, PA
15 studies for Non-Small Cell Lung Cancer are looking for participants at sites in and around York (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
RecruitingPhase 2
- Cancer Care Associates Of York /ID# 270971, York
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RecruitingPhase 3
- WellSpan Health-York Cancer Center, York
- WellSpan Health-York Hospital, York
- UPMC Memorial, York
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecruitingPhase 1/2
- WellSpan York Cancer Center, York
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
RecruitingPhase 3
- WellSpan Oncology Research, York
Pan-tumor MRD Study
RecruitingObservational study
- Cancer Care Associates of York (CCAY), York
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
RecruitingPhase 3
- WellSpan Oncology Research, York
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
RecruitingPhase 3
- Research Site, York
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
RecruitingObservational study
- WellSpan Medical Oncology & Hematology at York Cancer Center, York
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RecruitingPhase 2
- WellSpan Health-York Cancer Center, York
- UPMC Memorial, York
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
RecruitingPhase 2
- Cancer Care Associates of York, York
- WellSpan Health-York Cancer Center, York
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RecruitingPhase 2/3
- Cancer Care Associates of York, York
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
RecruitingPhase 2
- Cancer Care Associates of York, York
- WellSpan Health-York Cancer Center, York
- WellSpan Health-York Hospital, York
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
RecruitingObservational study
- WellSpan Health - York Cancer Center, York
GEMINI-NSCLC: NSCLC Biomarker Study
RecruitingObservational study
- Cancer Care Associates of York, York
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
RecruitingPhase 1/2
- Cancer Care Associates of York (site 206), York
Non-Small Cell Lung Cancer trials in other cities
- Houston, TX145 studies
- New York City, NY121 studies
- Arlington, VA104 studies
- Nashville, TN97 studies
- Boston, MA90 studies
- Los Angeles, CA87 studies
- St. Louis, MO73 studies
- Chicago, IL61 studies
- Baltimore, MD60 studies
- San Antonio, TX59 studies
- Columbus, OH57 studies
- Washington, DC55 studies
Other studies in York
- Cancer (all types)8 studies
- Breast Cancer8 studies
- Lung Cancer8 studies
- Head and Neck Squamous Cell Carcinoma7 studies
- Ovarian Cancer6 studies
- Prostate Cancer5 studies
- Coronary Artery Disease5 studies
- Esophageal Cancer4 studies
- Triple-Negative Breast Cancer4 studies
- Colorectal Cancer4 studies
- Endometrial Cancer4 studies
- Colon Cancer3 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.